These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 35152911)
1. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report. Saishu Y; Yoshida T; Seino Y; Nomura T J Med Case Rep; 2022 Feb; 16(1):61. PubMed ID: 35152911 [TBL] [Abstract][Full Text] [Related]
2. Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies. Kitazaki Y; Yamamura O; Usui K; Ueno A; Sanada S; Sasaki H; Endo Y; Enomoto S; Ikawa M; Nakamoto Y; Hamano T Intern Med; 2023; 62(20):3013-3020. PubMed ID: 37839874 [TBL] [Abstract][Full Text] [Related]
3. [An autopsy case of nivolumab-induced myasthenia gravis and myositis]. Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature. Patelli G; Bencardino K; Tosi F; Pugliano M; Lanzani F; Innocenti A; Rinaldo A; Mauri G; Cerea G; Sartore-Bianchi A; Torre M; Agostoni EC; Siena S J Med Case Rep; 2021 Feb; 15(1):32. PubMed ID: 33526108 [TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623 [TBL] [Abstract][Full Text] [Related]
6. [A case of myasthenia gravis and myositis induced by nivolumab]. Konoeda F; Suzuki S; Nishimoto Y; Hoshino H; Takagi M Rinsho Shinkeigaku; 2017 Jul; 57(7):373-377. PubMed ID: 28674287 [TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis. Wang C; Zeng H; Fang W; Song L Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830 [TBL] [Abstract][Full Text] [Related]
8. [A case of myasthenia gravis and myositis induced by pembrolizumab]. Noda T; Kageyama H; Miura M; Tamura T; Ito H Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124 [TBL] [Abstract][Full Text] [Related]
10. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies. Fazal M; Prentice DA; Kho LK; Fysh E Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231 [TBL] [Abstract][Full Text] [Related]
11. A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer. Komatsu M; Hirai M; Kobayashi K; Hashidate H; Fukumoto J; Sato A; Usuda H; Tanaka K; Takahashi K; Kuwabara S BMC Gastroenterol; 2021 Aug; 21(1):333. PubMed ID: 34445963 [TBL] [Abstract][Full Text] [Related]
13. Plasma Exchange in Patients With Myositis due to Immune Checkpoint Inhibitor Therapy. Katyal N; Katsumoto TR; Ramachandran KJ; Yunce M; Muppidi S J Clin Neuromuscul Dis; 2023 Dec; 25(2):89-93. PubMed ID: 37962196 [TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report. Wang C; Zhong B; He J; Liao X Medicine (Baltimore); 2023 Apr; 102(15):e33550. PubMed ID: 37058040 [TBL] [Abstract][Full Text] [Related]
15. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event. Lin X; Guan W; Li B; Deng H; Chen Y; Yang Y; Qiu G; Xie X; Zhou C Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):780-787. PubMed ID: 37339370 [TBL] [Abstract][Full Text] [Related]
16. Myositis as a neuromuscular complication of immune checkpoint inhibitors. Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961 [TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270 [TBL] [Abstract][Full Text] [Related]
18. Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature. Veccia A; Kinspergher S; Grego E; Peterlana D; Berti A; Tranquillini E; Caffo O Anticancer Drugs; 2020 Jun; 31(5):540-544. PubMed ID: 32011360 [TBL] [Abstract][Full Text] [Related]
19. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma. Fazel M; Jedlowski PM Case Reports Immunol; 2019; 2019():2539493. PubMed ID: 31183226 [TBL] [Abstract][Full Text] [Related]
20. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]